OMED News Alert Oncomed Pharmaceuticals Inc (OMED) 20.92 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncomed Pharmaceuticals Inc (OMED) 20.92 $OMED

OncoMed Pharmaceuticals (OMED) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 7:54AM CST
OncoMed Pharmaceuticals has been witnessing a flat trend in its current year loss estimate and its share price has been falling for past few weeks
OMED: 20.92 (+0.76), AFFX: 9.80 (+0.05)

3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user  Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), OMED: 20.92 (+0.76), GILD: 91.29 (+1.84), TEVA: 57.09 (+0.33), EPZM: 17.71 (+0.01), AGIO: 109.67 (+2.45), SNY: 46.35 (+0.50), FOLD: 7.94 (+0.06), XLRN: 38.80 (+0.80), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48)

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014
M2 - Thu Dec 04, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/24zmv5/metastatic) has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - MedImmune, LLC - Novartis AG - Onyx Pharmaceuticals, Inc. - Active Biotech AB - Hutchison MediPharma Limited - OncoMed Pharmaceuticals, Inc. - Mirna Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/24zmv5/metastatic
OMED: 20.92 (+0.76), AZN: 70.44 (+0.26), NVS: 93.91 (+0.66)

OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer
GlobeNewswire - Mon Dec 01, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's "PINNACLE" clinical trial of its anti-Notch2/3 cancer stem cell antibody, tarextumab (OMP-59R5), for the treatment of small cell lung cancer (SCLC).
OMED: 20.92 (+0.76)

OncoMed Presents New Clinical and Biomarker Data From Its Tarextumab and Demcizumab Clinical Trials at the EORTC-NCI-AACR Symposium
GlobeNewswire - Fri Nov 21, 7:00AM CST
Biomarker Studies Demonstrate On-Target Effects of Tarextumab Against Notch Pathway and Cancer Stem Cells in Patients With Pancreatic Cancer
OMED: 20.92 (+0.76)

OncoMed Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
GlobeNewswire - Thu Nov 20, 3:30PM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Sunil Patel, Chief Financial Officer, Senior Vice President, Corporate Development and Finance, will speak at the 26th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 pm Eastern Time.
OMED: 20.92 (+0.76)

OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial of Anti-Notch1 (OMP-52M51) in Oral Plenary Session at the 26th EORTC-NCI-AACR Symposium
GlobeNewswire - Wed Nov 19, 6:50AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented data today from the company's ongoing Phase 1a clinical trial of anti-Notch1 (OMP-52M51) in patients with certain advanced solid tumors during an oral plenary session at the 26 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
OMED: 20.92 (+0.76)

5 Things Celgene Corporation's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 6:51AM CST
Source: U.S. Department of Agriculture via Flickr . Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher . For the quarter, Celgene...
OMED: 20.92 (+0.76), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), CELG: 109.60 (+3.48)

Oncomed Pharmaceuticals' (OMED) CEO Paul Hastings on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST

OMED: 20.92 (+0.76)

OncoMed beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:36PM CST

OMED: 20.92 (+0.76)

OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Nov 04, 3:02PM CST
Raises Year-End Cash Balance Guidance to Over $225 Million From $215 Million
OMED: 20.92 (+0.76)

OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S.
GlobeNewswire - Mon Nov 03, 7:37AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, has been granted a new patent (U.S. Patent No. 8,858,941) in the United States for OncoMed's anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and use of the bispecific antibody in the treatment of cancer. The new patent includes both composition-of-matter and method of treatment claims for the antibody. Related patent applications are pending in the United States, Europe, Japan, China and a number of other countries worldwide.
OMED: 20.92 (+0.76)

OncoMed to Present Clinical and Preclinical Data at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting
GlobeNewswire - Thu Oct 30, 7:31AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present clinical data from three anti-cancer stem cell clinical programs at the 26 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting to be held November 18-21, 2014 in Barcelona, Spain.
OMED: 20.92 (+0.76)

OncoMed to Announce Financial Results for the Third Quarter 2014 on Tuesday, November 4, 2014, After Close of U.S.-Based Financial Markets
GlobeNewswire - Wed Oct 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4, 2014, after the close of U.S.-based financial markets. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review the results beginning at 1:30 p.m. Pacific Time (PT)/4:30 p.m. Eastern Time (ET).
OMED: 20.92 (+0.76)

Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 20.92 (+0.76), AGIO: 109.67 (+2.45), CELG: 109.60 (+3.48)

Global Pancreatic Cancer Market 2014-2018: Key Vendors are Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer
M2 - Thu Oct 09, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjxws/global_pancreatic) has announced the addition of the "Global Pancreatic Cancer Market 2014-2018" report to their offering. Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, accounting for 6.8 percent of the total cancer deaths in the US. The analysts forecast the Global Pancreatic Cancer market to grow at a CAGR of 10.70 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pancreatic Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat different types of pancreatic cancer. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - AB Science - AbGenomics International - Aduro Biotech - Aphios - Celgene - Celsion - Eli Lilly - F. Hoffmann-La Roche - Gilead Sciences - Halozyme Therapeutics - Merrimack Pharmaceuticals - Momenta Pharmaceuticals - Novartis - OncoMed Pharmaceuticals - OncozymePharma - Ostuka Holdings - Pfizer - Rexahn Pharmaceuticas - Zeria Pharmaceutica For more information visit http://www.researchandmarkets.com/research/cm...pancreatic
MACK: 10.91 (+0.36), OMED: 20.92 (+0.76), GILD: 91.29 (+1.84), LLY: 70.16 (+0.42), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.70 (-0.02), IMMU: 4.41 (+0.13), ONCY: 0.49 (unch), OMED: 20.92 (+0.76), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06), MACK: 10.91 (+0.36), SNTA: 2.63 (+0.02), INSY: 41.52 (+0.51), HALO: 9.34 (+0.31), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Oct 07, 7:39AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed, will speak today at the 13 Annual BIO Investor Forum being held in San Francisco, CA. To access the live webcast and subsequent archived recording for the presentation, please visit the Investors tab on the OncoMed website at www.oncomed.com.
OMED: 20.92 (+0.76)

OncoMed Pharmaceuticals Announces Selection of First Small Molecule Product Candidate Targeting the Wnt Pathway Under Collaboration With Bayer Pharma AG
GlobeNewswire - Tue Sep 30, 7:31AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the advancement of the first small molecule Wnt pathway inhibitor under its collaboration with Bayer Pharma AG. The small molecule product candidate is advancing to preclinical development triggering a $2 million milestone payment to OncoMed.
OMED: 20.92 (+0.76)

OncoMed Presents Encouraging Data From Clinical Trials of Tarextumab (Anti-Notch2/3) in Pancreatic Cancer and Small Cell Lung Cancer at the ESMO 2014 Congress
GlobeNewswire - Mon Sep 29, 6:00AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented promising data on safety and anti-tumor activity from the ALPINE and PINNACLE Phase 1b clinical studies of tarextumab (anti-Notch2/3, OMP-59R5) at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain.
OMED: 20.92 (+0.76)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 72

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading

Top 5 Most Recently Viewed Articles

Alphabet's Q2 Earnings: AI Insights and Market Reactions Await

Updated Category News Views 187

Alphabet's Q2 Earnings Report: A Focus on AI Growth Alphabet (NASDAQ: GOOGL), the parent company of Google, is poised to release its second quarter earnings soon. Many analysts and investors are keenly awaiting details that might reveal how the company’s artificial intelligence (AI) endeavors are transforming into tangible revenue streams. With the surge in interest...

Continue Reading
Join the Class Action Against Dentsply Sirona for Investor Rights

Updated Category News Views 91

Important Notice for Dentsply Sirona Inc. Shareholders The Gross Law Firm has issued a notice for shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY). Shareholders who acquired shares during the recently identified class period are encouraged to reach out regarding the opportunity to be appointed as lead plaintiff. Securing this position is not a prerequisite for...

Continue Reading
Major Insider Sale by James Davis at American Woodmark Revealed

Updated Category News Views 447

Insider Activity Spotlight on American Woodmark James Davis, a Board Member of American Woodmark (NASDAQ: AMWD), has made headlines recently by selling a significant number of shares, which has sparked various reactions in the market. Understanding Recent Transactions: In a recent SEC filing, it was reported that DAVIS sold 1,250 shares of American Woodmark, amounting to...

Continue Reading
Ivybrook's $5K Franchise Incentive Targets Educators

Updated Category News Views 28

Franchise ownership might just feel within reach for educators eying a new chapter, thanks to Ivybrook Academy’s fresh incentive. The renowned half-day preschool franchise is now offering a cool $5,000 cut off the initial franchise fee to educators diving into franchise ownership. It’s a nod to those who spend their days molding young minds. Opening Doors for...

Continue Reading
NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

Updated Category News Views 61

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Continue Reading